Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.715 USD | -0.96% | -4.55% | -40.20% |
May. 15 | HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating | MT |
May. 14 | Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 |
Business Summary
Number of employees: 29
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sodium Thiosulfate
100.0
%
| 2 | 100.0 % | 29 | 100.0 % | +1,335.37% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 29 | 100.0 % | +1,335.37% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 09-07-06 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Adrian Haigh
COO | Chief Operating Officer | 64 | 14-04-24 |
Mark Gowland
AUD | Comptroller/Controller/Auditor | 52 | 15-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 11-08-24 |
Khalid Islam
CHM | Chairman | 67 | 14-04-24 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Adrian Haigh
COO | Chief Operating Officer | 64 | 14-04-24 |
Marco Brughera
BRD | Director/Board Member | 70 | 16-08-09 |
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 09-07-06 |
Jodi Cook
BRD | Director/Board Member | 56 | 19-09-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,322,141 | 22,174,779 ( 81.16 %) | 0 | 81.16 % |
Company contact information
Fennec Pharmaceuticals, Inc.
Research Triangle Park 68 T.W. Alexander Drive
27709, Durham
+919 636 4530
http://www.fennecpharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.20% | 185M | |
+14.74% | 118B | |
+12.62% | 106B | |
-3.29% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-19.58% | 15.56B | |
+6.32% | 13.63B | |
+28.58% | 12.27B |
- Stock Market
- Equities
- FENC Stock
- Company Fennec Pharmaceuticals Inc.